

## ZKB Tracker Certificate Dynamic on MGF BioSciences hCHF

11.02.2021 - Open End | Swiss Security Code 56 679 913

### Summary

This Summary is to be understood as an introduction to the present Final Terms. Any investment decision in relation to the products must be based on the information contained in the Base Prospectus and in these Final Terms in their entirety and not on the Summary. In particular, each investor should consider the risk factors contained in these Final Terms and in the Base Prospectus.

The Issuer can only be held liable for the content of this Summary if the Summary is misleading, incorrect or contradictory when read together with the other parts of the Final Terms and the Base Prospectus.

Information on the securities
<b>Type of product:</b> ZKB Tracker Certificate Dynamic <b>SSPA Category:</b> Tracker Certificate (1300, acc. to the Swiss Derivative Map) <b>ISIN:</b> CH0566799133 <b>Symbol:</b> MGBIOZ <b>Issuer:</b> Zürcher Kantonalbank <b>Underlying:</b> MGF BioSciences hCHF <b>Initial Fixing Date:</b> 3 February 2021 <b>Settlement Date:</b> 11 February 2021 <b>Final Fixing Date:</b> --- (Open End) <b>Redemption Date:</b> --- (Open End) <b>Type of settlement:</b> cash
Information concerning the offer and admission to trading
<b>Place of the offer:</b> Switzerland <b>Notional Amount/Denomination/Trading Units:</b> CHF 20'000'000.00/CHF 100.00/1 Structured Product or multiples thereof <b>Issue price:</b> CHF 100.00 <b>Selling restrictions:</b> EEA, U.S.A./U.S. persons, United Kingdom, Guernsey <b>Information on listing:</b> Application to list on the SIX Swiss Exchange will be filed, the first provisory trading day will be 11 February 2021

### Final Terms

#### 1. Product Description

#### Product Category/Name

Participation Product/Tracker Certificate (1300, according to the Swiss Derivative Map provided by the Swiss Structured Products Association)

#### Regulatory Notification

**This product does not constitute a collective investment scheme within the meaning of the Swiss Federal Act on Collective Investment Schemes (CISA) and it is not subject to authorisation or supervision by FINMA. The issuer risk is borne by investors.**

#### Investment Profile

The composition of the Underlying of this Structured Product is managed **dynamically** and **discretionary** over the course of its term.

The investment manager, MG Finance, invests in stocks active in the field of Health Care and Biotech.

Further information about the investment strategy – if available – can be obtained free of charge from Zürcher Kantonalbank, Bahnhofstrasse 9, 8001 Zürich, department VRIE or by way of e-Mail address [documentation@zkb.ch](mailto:documentation@zkb.ch).

#### Title Universe

The Title Universe consists of stocks listed on a recognised stock exchange. In addition to investing in equities, the Investment Manager may decide to make a cash allocation, invest in bond ETFs or in so called Short-ETFs, if considered necessary to reduce exposure to the equity market. The Underlying constituents are listed at a recognized exchange (World Federation of Exchanges or FESE (Federation of European Securities Exchanges)). The current composition of the Underlying can be found under [www.zkb.ch/strukturierteprodukte](http://www.zkb.ch/strukturierteprodukte).

<b>Rebalancing</b>	The Investment Manager rebalances the portfolio composition based on its qualified evaluation of the market. The Investment Manager considers only Underlying Components which provide sufficient liquidity and tradability. The Rebalancing is based on net prices of the Underlying Components (average of the net prices of the Underlying Components converted into the basket currency by the Issuer). The rebalancing period may be prolonged by the Issuer due to limited tradability. The current basket composition is listed in the Annex to this termsheet.					
<b>Issuer</b>	Zürcher Kantonalbank, Zurich					
<b>Rating of the Issuer</b>	Standard & Poor's AAA, Moody's Aaa, Fitch AAA					
<b>Lead Manager, Paying Agent, Exercise Agent and Calculation Agent</b>	Zürcher Kantonalbank, Zurich					
<b>Investment Manager</b>	<p>MG Finance SA, Pully</p> <p>MG Finance SA is a securities dealer according to the Swiss Federal Act on Securities Exchanges and Securities Trading (BEHG; SR 954.1), MG Finance SA is subject to the prudential supervision of the FINMA, Laupenstrasse 27, CH-3003 Bern, <a href="http://www.finma.ch">http://www.finma.ch</a>.</p> <p>The Investment Manager may not only act as distributor of the Structured Product and/or Investment Manager in relation to the Underlying but also as asset manager or financial advisor in relation to the investors in the Structured Products. This may lead to potential conflicts between the interests of the investors and the interests of the Investment Manager. The Investment Manager has taken all necessary measures to avoid such potential conflict of interest or, if such avoidance is not reasonably possible, will disclose such conflict of interest to the investors concerned.</p>					
<b>Symbol/ Swiss Security Code/ISIN</b>	<b>MGBIOZ/</b> 56 679 913/CH0566799133					
<b>Notional Amount/Denomination/ Trading Units</b>	CHF 20'000'000.00/CHF 100.00/1 Structured Product or multiples thereof					
<b>Number of Structured Products</b>	Up to 200'000, with the right to increase					
<b>Issue Price</b>	<b>CHF 100.00</b> /100.00% of Basket Value on the Initial Fixing Date					
<b>Currency</b>	CHF					
<b>Underlying per Initial Fixing Date</b>	<b>Component</b>	<b>ISIN / Bloomberg</b>	<b>Related Exchange</b>	<b>*Currency / Initial Fixing Value</b>	<b>Weight in %</b>	<b>No. of Shares/ Amount</b>
	10x Genomics Inc	US88025U1097/ TXG UW	NASDAQ GS	USD 180.26874	2.00	0.012340
	Abiomed Inc	US0036541003/ ABMD UW	NASDAQ GS	USD 328.92843	1.00	0.003382
	Allakos Inc	US01671P1003/ ALLK UW	NASDAQ GS	USD 137.53493	1.50	0.012131
	AquaBounty Technologies Inc	US03842K2006/ AQB UR	NASDAQ	USD 10.88683	1.00	0.102169
	Arcturus Therapeutics Holdings Inc	US03969T1097/ ARCT UQ	NASDAQ GM	USD 80.81522	1.00	0.013763
	Arcus Biosciences Inc	US03969F1093/ RCUS UN	New York Stock Exchange	USD 39.49162	1.50	0.042248
	Arvinas Inc	US04335A1051/ ARVN UW	NASDAQ GS	USD 82.19183	1.50	0.020299
	Beam Therapeutics Inc	US07373V1052/ BEAM UW	NASDAQ	USD 100.33295	1.50	0.016629
	BeiGene Ltd	US07725L1026/ BGNE UW	NASDAQ GS	USD 360.99654	2.00	0.006162
	Biomarin Pharmaceutical Inc	US09061G1013/ BMRN UW	NASDAQ	USD 83.37610	2.00	0.026682
	Bionano Genomics Inc	US09075F1075/ BNGO UR	NASDAQ CM	USD 11.86178	2.50	0.234429
	BioTelemetry Inc	US0906721065/ BEAT UW	NASDAQ	USD 71.80327	1.00	0.015491
	Castle Biosciences Inc	US14843C1053/ CSTL UQ	NASDAQ GM	USD 82.75881	1.00	0.013440

Cerner Corp	US1567821046/ CERN UW	NASDAQ	USD	2.00	0.027838
Charles River Laboratories International Inc	US1598641074/ CRL UN	New York Stock Exchange	USD	2.00	0.008315
Codexis Inc	US1920051067/ CDXS UW	NASDAQ	USD	1.00	0.039900
Coherus	US19249H1032/ CHRS UQ	NASDAQ GM	USD	2.00	0.127836
BioSciences Inc	CH0334081137/ CRSP UQ	NASDAQ GM	USD	3.00	0.020163
CRISPR Therapeutics AG	US2521311074/ DXCM UW	NASDAQ	USD	2.00	0.005717
Dexcom Inc	US28106W1036/ EDIT UW	NASDAQ	USD	2.00	0.035140
Editas Medicine Inc	US30063P1057/ EXAS UR	NASDAQ CM	USD	3.00	0.023750
Exact Sciences Corp	US3795772082/ GMED UN	New York Stock Exchange	USD	2.00	0.035707
Globus Medical Inc	US40131M1099/ GH UW	NASDAQ	USD	2.00	0.014044
Guardant Health Inc	IE0005711209/ ICLR UW	NASDAQ GS	USD	2.00	0.010978
Icon PLC	US44930G1076/ ICUI UW	NASDAQ GS	USD	1.00	0.005322
ICU Medical Inc	US45166A1025/ IDYA UW	NASDAQ GS	USD	1.00	0.059294
IDEAYA Biosciences Inc	US4523271090/ ILMN UW	NASDAQ	USD	2.00	0.005245
Illumina Inc	US45332Y1091/ NARI UW	NASDAQ GS	USD	2.00	0.021689
Registered Shs Inari Medical Inc	US45337C1027/ INCY UW	NASDAQ	USD	2.00	0.024354
Incyte Corp	US45784P1012/ PODD UW	NASDAQ GS	USD	2.00	0.008105
Insulet Corp	US45826J1051/ NTLA UQ	NASDAQ	USD	2.00	0.032588
Intellia Therapeutics Inc	US46120E6023/ ISRG UW	NASDAQ	USD	2.00	0.002969
Intuitive Surgical Inc	US46185L1035/ NVTA UN	New York Stock Exchange	USD	2.00	0.042245
Invitae Corp	US46266C1053/ IQV UN	New York Stock Exchange	USD	2.00	0.012114
IQVIA Holdings Inc	US60770K1079/ MRNA UW	NASDAQ	USD	2.00	0.013544
Moderna Inc	US63009R1095/ NSTG UQ	NASDAQ GM	USD	1.00	0.014917
NanoString Technologies Inc	US64125C1099/ NBIX UW	NASDAQ	USD	2.00	0.019643
Neurocrine Biosciences Inc	JE00BYSS4X48/ NVCR UW	NASDAQ	USD	2.00	0.012918
NovoCure Limited	US69404D1081/ PACB UW	NASDAQ GS	USD	2.50	0.080325
Pacific Biosciences of California Inc	US71535D1063/ PSNL UQ	NASDAQ GM	USD	1.50	0.041034
Personalis Inc	US72940R3003/ PSTI UQ	NASDAQ GM	USD	1.00	0.172013
Pluristem Therapeutics Inc	US69354M1080/ PRAH UW	NASDAQ GS	USD	2.00	0.018215
PRA Health Sciences Inc	US74019P1084/ DTIL UW	NASDAQ GS	USD	1.00	0.080177
Precision BioSciences Inc	US74834L1008/ DGX UN	New York Stock Exchange	USD	2.00	0.017492
Quest Diagnostics Inc	US75886F1075/ REGN UW	NASDAQ GS	USD	3.00	0.006761
Regeneron Pharmaceuticals Inc	US8006771062/ SGMO UW	NASDAQ	USD	1.00	0.079268
Sangamo Therapeutics Inc	US80810D1037/ SDGR UW	NASDAQ	USD	1.50	0.017362
Schrodinger Inc	US81181C1045/ SGEN UW	NASDAQ GS	USD	2.00	0.013608
Seagen Inc					

Sorrento Therapeutics Inc	US83587F2020/ SRNE UR	NASDAQ CM	USD	1.00	0.079221
Syneos Health Inc	US87166B1026/ SYNH UW	NASDAQ GS	USD	2.00	0.028919
Teladoc Health Inc	US87918A1051/ TDOC UN	New York Stock Exchange	USD	4.00	0.016324
Thermo Fisher Scientific Inc	US8835561023/ TMO UN	New York Stock Exchange	USD	2.00	0.004405
Twist Bioscience Corporation	US90184D1000/ TWST UW	NASDAQ	USD	2.00	0.011656
Uniqure B.V.	NL0010696654/ QURE UW	NASDAQ GS	USD	1.00	0.030795
Veracyte Inc	US92337F1075/ VCYT UQ	NASDAQ GM	USD	1.00	0.015007
Zai Lab Ltd	US98887Q1040/ ZLAB UQ	NASDAQ	USD	2.00	0.012903
			172.40656		

\* Local taxes, transactions fees and foreign commissions are, if applicable, included in the Initial Fixing Value of each component and are thus borne by the holders of the Structured Product. This applies particularly, though not exclusively, when exercising rights associated with the Structured Product and/or a Rebalancing.

<b>Basket Value</b>	CHF 100.00 on Initial Fixing Date
<b>Ratio</b>	1 ZKB Tracker Certificate Dynamic represents 1 Underlying
<b>Dividend Payments</b>	No dividends will be paid out. The dividend as a whole will be reinvested into the Structured Product in the form of a net dividend.
<b>Initial Fixing Date</b>	3 February 2021 The Issuer has the right to expand the time period for the Initial Fixing if required by current market conditions e.g. liquidity.
<b>Settlement Date</b>	11 February 2021
<b>Redemption right of the Issuer</b>	The Issuer has the right to redeem the outstanding Structured Products quarterly on the 15th day of March, June, September and December (fixing date; modified following), for the first time on 15 December 2021. On the fixing date, the redemption amount is determined, which is governed by the information under the section Redemption Method. The Issuer has the right to expand the time period for the Final Fixing if required by current market conditions e.g. liquidity. The announcement and thus the declaration of intent to exercise the Redemption right is made with a notice period of 20 banking days via the official publication channel of the SIX Swiss Exchange. No statement of reasons is required. The redemption will be executed with a value date of 5 bank working days after the fixing date (Redemption Date).
<b>Right to return of the Investor</b>	In addition to the possibility of selling the Structured Products in the secondary market, the investor has the right to return the product quarterly per 15th day of the months March, June, September and December (fixing date; modified following) to the Issuer, for the first time on 15 December 2021. On the fixing date, the redemption amount is determined, which is governed by the information under the section Redemption Method. The Issuer has the right to expand the time period for the Final Fixing if required by current market conditions e.g. liquidity. The declaration of intent to exercise the Right to return must be received no later than 5 banking days before the respective fixing date (exercise date) by Zürcher Kantonalbank and must be sent to the following address: by letter post to Zürcher Kantonalbank, Sales Structured Products, IHHV, P.O. Box, 8010 Zürich or by email to <a href="mailto:derivate@zkb.ch">derivate@zkb.ch</a> . The repayment will be executed with a value date of 5 bank working days after the fixing date (Redemption Date). Should the Structured Products of the Investor be deposited in a custodian bank, the Investor needs additionally and in due time advise/inform his custodian bank according the notice of redemption.
<b>Initial Fixing Level</b>	3 February 2021, Net price of the Components of the Underlying on a best effort basis.

## Redemption Method

On Redemption Date, investors receive for every certificate 100% of the Underlying. The net asset value is calculated using the following formula on each trading day t:

$$IV_t = IV_{t-1} + IV_{t-1} * \sum_{i=1}^n \left[ w_t^i * \left( \frac{BW_t^i - BW_{t-1}^i}{BW_{t-1}^i} * \frac{FX_t^i}{FX_{t-1}^i} + FXRoll_{t-1,t}^i \right) \right]$$

Fees

Where:

$IV_t$  Intrinsic value on trading day t ( $IV_0$  = CHF 100.00)

n Number of Underlyings

$w_t^i$  Weight in % of Underlying i at time t

$BW_t^i$  Price of Underlying i at time t

$FX_t^i$  Price of the currency of Underlying i at time t

$FXRoll_{t-1,t}^i$  Net interest income / interest expense in % of FX Rolls between time t-1 and t in the currency of underlying component i

Negative interests could be charged on any potential Cash Components (reference interest rate of the respective currency). This has a negative impact on the value of the structured product.

If capital events that were unknown at the time of issue take place during the life of the ZKB Tracker Certificate Dynamic, they shall be taken into account by adjusting the weighting of the affected Component of the Underlying accordingly.

## Listing

Application to list on the SIX Swiss Exchange will be filed, the first provisory trading day will be 11 February 2021.

## Annual Fee

Up to 1.65% p.a. The Annual Fee will be charged based on the value of the Structured Product and is pro rata temporis included in the trading price. Of the Annual Fee, the Issuer receives up to 0.35% p.a. and the Investment Manager receives 1.30% p.a. for their relevant duties.

## Rebalancing Fee

A Rebalancing Fee of 0.10% of the transaction value will be charged per Rebalancing.

## Clearing House

SIX SIS AG/Euroclear/Clearstream

## Distribution fees

No distribution fees in the form of a discount on issue price, reimbursement of a part of the issue price or other one-off and/or periodic charges are paid out to one or several distribution partners of this Structured Product.

## Sales: 044 293 66 65

SIX Telekurs: .zkb

Reuters: ZKBSTRUCT

Internet: [www.zkb.ch/finanzinformationen](http://www.zkb.ch/finanzinformationen)

Bloomberg: ZKBY <go>

## Key Elements of the Product

In terms of value, buying a ZKB Tracker Certificate Dynamic is equivalent to buying the Underlying less any Fees. A single, low-cost transaction gives investors the opportunity to participate fully in the performance of the Underlying. Dividend Payments of underlying components in the basket are paid out to the investor by means of Dividend reinvestment in the Underlying. Redemption is based on the weighted value of Underlying components on the Fixing Date.

## Taxes

The Issuer reports the taxable factors (change to previous year's value) divided in the components income and capital gain to the Swiss Federal Tax Administration on 31 October each year. The income part is subject to Swiss income tax for private investors with Swiss tax domicile as per reporting date. The capital gain part is not subject to Swiss income tax. The product is not subject to Swiss withholding tax. The Federal securities transfer stamp tax is not levied on secondary market transactions. This product may be subject to additional withholding taxes or duties, such as related to FATCA, Sect. 871(m) U.S. Tax Code or foreign financial transaction taxes. Any payments due under this product are net of such taxes or duties.

The information above is a summary only of the Issuer's understanding of current law and practice in Switzerland relating to the taxation of Structured Products. The relevant tax law and practice may change. The Issuer does not assume any liability in connection with the above information. The tax information only provides a general overview and can not substitute the personal tax advice to the investor.

## Documentation

This document is a non-binding English translation of the Final Terms (Endgültige Bedingungen) published in German and constituting the Final Terms in accordance with article 45 of the Federal Act on Financial Services (FinSA). The English language translation is provided for convenience only.

The binding German version of these Final Terms supplements the Base Prospectus approved by the SIX Exchange Regulation Ltd and published in German by the Issuer on 16 November 2020. These Final Terms constitute a Simplified prospectus pursuant to article 5 para. 2 CISA in the version dated 1 March 2013. Together with the Base Prospectus (and together with any supplements) these Final Terms form the product documentation for this issue.

If this Product was the first time issued under the Base Prospectus of 16 November 2020, these Final Terms must be read in conjunction with the General Terms of the Securities (Allgemeine Bedingungen der Derivate), the Additional Terms and the Information on the Underlyings in the Base Prospectus of 16 November 2020. If this Product has been issued prior to the date of the Base Prospectus of 16 November 2020, these Final Terms shall be read in conjunction with the Base Prospectus of 16 November 2020 and together with the Existing Terms of the Products from the version of the Issuance Programme or Base Prospectus in force at the time of issuance that has been incorporated by reference in this Base Prospectus.

The Base Prospectus of the Issuer dated 16 November 2020 will cease to be valid on 16 November 2021. From and including this date, these Final Terms must be read together with the latest valid version of the Base Prospectus of the Issuer (including the information incorporated by reference into the latest valid version of the Base Prospectus from the Base Prospectus under which the Products the first time were issued), which follows the Base Prospectus of 16 November 2020.

Except as otherwise defined in these Final Terms, the terms used in these Final Terms have the meaning given to them in the Base Prospectus. In case of discrepancies between information or the provisions in these Final Terms and those in the Base Prospectus, the information and provisions in these Final Terms shall prevail. In the event of a listing of the products, the product documentation will be adapted, if and to the extent necessary, in accordance with the requirements of the relevant exchange. The present products will be issued in the form of uncertificated securities (Wertrechte) and registered as book-entry securities (Bucheffekten) with SIX SIS AG. Investors have no right to require the issuance of any certificates or any proof of evidence for the products.

**These Final Terms and the Base Prospectus can be ordered free of charge at Zürcher Kantonalbank, Bahnhofstrasse 9, 8001 Zurich, dept. VRIE or by e-mail at [documentation@zkb.ch](mailto:documentation@zkb.ch). They are also available on <https://www.zkb.ch/finanzinformationen>.**

## Information on the Underlying

Information on the performance of the Underlying/a component of the Underlying is publicly available on [www.bloomberg.com](http://www.bloomberg.com). Current annual reports are published on the website of the respective business entity. The transfer of the Underlying/a component of the Underlying is conducted in accordance with their respective statutes.

## Notices

Any notice by the Issuer in connection with these Structured Products, in particular any notice in connection with modifications of the terms and conditions will be validly published on the website <https://www.zkb.ch/finanzinformationen> under the relevant Structured Product. The Swiss security code search button will lead you directly to the relevant Structured Product. The notices will be published in accordance with the rules issued by SIX Swiss Exchange for IBL (Internet Based Listing) on the website <https://www.six-exchange-regulation.com/en/home/publications/official-notice.html>

## Governing Law/Jurisdiction

Swiss Law/Zurich

## 2. Profit and Loss Expectations after Year 1

### Profit and Loss Expectations after Year 1

ZKB Tracker Certificate Dynamic

Basket		Redemption	
Value	Percent	ZKB Tracker Certificate Dynamic	Performance %
CHF 40.00	-60.00%	CHF 39.34	-60.66%
CHF 60.00	-40.00%	CHF 59.01	-40.99%
CHF 80.00	-20.00%	CHF 78.68	-21.32%
CHF 100.00	+0.00%	CHF 98.35	-1.65%
CHF 120.00	+20.00%	CHF 118.02	18.02%
CHF 140.00	+40.00%	CHF 137.69	37.69%
CHF 160.00	+60.00%	CHF 157.36	57.36%

Source: Zürcher Kantonalbank

The performance of the ZKB Tracker Certificate Dynamic is analog to the performance of the Underlying less any Fees. Rebalancing Fees are not included in the table above.

The figures in the table above are valid after Year 1 only and cannot be considered as a price indication for the present Structured Product during its lifetime. The price quoted in the secondary market can differ substantially from the table above.

## 3. Material Risks for Investors

### Credit Risk Relating to Issuer

Obligations under these Structured Products constitute direct, unconditional and unsecured obligations of the Issuer and rank pari passu with other direct, unconditional and unsecured obligations of the Issuer. The value of the Structured Product does not only depend on the performance of the Underlying and other developments in the financial markets, but also on the solvency of the Issuer, which may change during the term of this Structured Product.

### Specific Product Risks

Structured Products are complex financial instruments, which entail considerable risks and, accordingly, are only suitable for investors who have the requisite knowledge and experience and understand thoroughly the risks connected with an investment in these structured products and are capable of bearing the economic risks.

ZKB Tracker Certificate Dynamic is an investment product whose price fluctuates to the same degree as the Underlying less any Fees. Depending on price trends, the price of a ZKB Tracker Certificate Dynamic could fall below the Issue Price. The risk profile of the ZKB Tracker Certificate Dynamic corresponds to that of the Underlying. The ZKB Tracker Certificate Dynamic is denominated in CHF. If the investor's reference currency differs from the CHF, the investor bears the risk between the CHF and his reference currency.

## 4. Additional Terms

### Modifications

If an extraordinary event as described in the Base Prospectus occurs in relation to the Underlying/a component of the Underlying or if any other extraordinary event occurs, which makes it impossible or particularly cumbersome for the Issuer, to fulfill its obligations under the Products or to calculate the value of the Products, the Issuer shall at its own discretion take all the necessary actions and, if necessary may modify the terms and conditions of these Products at its own discretion in such way, that the economic value of the Products after occurrence of the extraordinary event corresponds, to the extent possible, to the economic value of the Products prior to the occurrence of the extraordinary event. Specific modification rules for certain types of Underlyings stated in the Base Prospectus shall prevail. If the Issuer determines, for whatever reason, that an adequate modification is not possible, the Issuer has the right to redeem the Products early.

### Market Disruptions

Compare specific provisions in the Base Prospectus.

### Substitution of Underlying

During the term of the Structured Product, changes in or substitution of the Underlying by the Calculation Agent can occur. In this case, it cannot be ruled out that such changes or substitutions will negatively affect the value of the Structured Product. Likewise, it cannot be ruled out that in the case of a Structured Product based on an index that changes in the composition of the index as a result of change or substitutions in respect of individual index components, for example, as a result of the withdrawal or addition of individual securities, may negatively influence the price of the index and accordingly the value of the Structured Product.

### Selling Restrictions

EEA, U.S.A./U.S. persons, United Kingdom, Guernsey

**Prudential Supervision**

As a bank within the meaning of the Swiss Federal Act on Banks and Savings Banks (BankG; SR 952.0) and a securities firm within the meaning of the Swiss Federal Act on Financial Institutions (FinlAG; SR 954.1), Zürcher Kantonalbank is subject to the prudential supervision of FINMA, Laupenstrasse 27, CH-3003 Bern, <https://www.finma.ch>.

**Recording of Telephone Conversations**

Investors are reminded that telephone conversations with trading or sales units of Zürcher Kantonalbank are recorded. Investors, engaging in telephone conversations with these units provide their tacit consent to the recording of their conversations.

**Further Information**

This document constitutes neither an offer nor a recommendation or invitation to purchase financial instruments and can't replace the individual investor's own judgement. The information contained in this document does not constitute investment advice but is intended solely as a product description. An investment decision should in any case be made on the basis of these Final Terms and the Base Prospectus. Particularly, before entering into a transaction, the investor should, if necessary with the assistance of an advisor, examine the conditions for investment in the Product in consideration of his personal situation with regard to legal, regulatory, tax and other consequences. Only an investor who is aware of the risks of the transaction and has the financial capacity to bear any losses should enter into such transactions.

**Material Changes**

Since the end of the last financial year or the date of the interim financial statements, there have been no material changes in the assets, financial or revenue position of the Issuer.

**Responsibility for the Final Terms**

Zürcher Kantonalbank, Zurich, assumes responsibility for the content of these Final Terms and hereby declares that, to its knowledge, the information contained in these Final Terms is correct and no material circumstances have been omitted.

Zurich, 3 February 2021, last update on 11 February 2021

Underlying on 08 02 2021

Component	ISIN / Bloomberg	Related Exchange	*Currency / Initial Fixing Value	Weight in %	No. of Shares/ Amount
10x Genomics Inc	US88025U1097/ TXG UW	NASDAQ GS	186.7500	2.01	0.012320
Abiomed Inc	US0036541003/ ABMD UW	NASDAQ GS	329.8800	0.97	0.003376
Allakos Inc	US01671P1003/ ALLK UW	NASDAQ GS	144.0000	1.52	0.012111
AquaBounty Technologies Inc	US03842K2006/ AQB UR	NASDAQ	9.6650	0.86	0.102000
Arcturus Therapeutics Holdings Inc	US03969T1097/ ARCT UQ	NASDAQ GM	86.1200	1.03	0.013740
Arcus Biosciences Inc	US03969F1093/ RCUS UN	New York Stock Exchange	41.4000	1.52	0.042178
Arvinas Inc	US04335A1051/ ARVN UW	NASDAQ GS	83.9350	1.48	0.020265
Beam Therapeutics Inc	US07373V1052/ BEAM UW	NASDAQ	119.6000	1.73	0.016602
BeiGene Ltd	US07725L1026/ BGNE UW	NASDAQ GS	373.8550	2.01	0.006152
Biomarin Pharmaceutical Inc	US09061G1013/ BMRN UW	NASDAQ	85.3500	1.98	0.026638
Bionano Genomics Inc	US09075F1075/ BNGO UR	NASDAQ CM	10.9300	2.23	0.234042
BioXcel Therapeutics Inc	US09075P1057/ BTAI UR	NASDAQ CM	58.6066	0.97	0.018960
Castle Biosciences Inc	US14843C1053/ CSTL UQ	NASDAQ GM	96.0300	1.12	0.013418
Cerner Corp	US1567821046/ CERN UW	NASDAQ	79.9050	1.94	0.027792
Charles River Laboratories International Inc	US1598641074/ CRL UN	New York Stock Exchange	278.5400	2.02	0.008301
Codexis Inc	US1920051067/ CDXS UW	NASDAQ	28.0400	0.97	0.039834
Coherus BioSciences Inc	US19249H1032/ CHRS UQ	NASDAQ GM	18.1800	2.02	0.127625
CRISPR Therapeutics AG	CH0334081137/ CRSP UQ	NASDAQ GM	169.3799	2.97	0.020130
Dexcom Inc	US2521311074/ DXCM UW	NASDAQ	413.2000	2.06	0.005708
Editas Medicine Inc	US28106W1036/ EDIT UW	NASDAQ	64.6900	1.98	0.035082
Exact Sciences Corp	US30063P1057/ EXAS UR	NASDAQ CM	149.4000	3.09	0.023711
Globus Medical Inc	US3795772082/ GMED UN	New York Stock Exchange	63.3000	1.97	0.035648
Guardant Health Inc	US40131M1099/ GH UW	NASDAQ	162.1900	1.98	0.014021
Icon PLC	IE0005711209/ ICLR UW	NASDAQ GS	201.9200	1.93	0.010960
ICU Medical Inc	US44930G1076/ ICUI UW	NASDAQ GS	209.1000	0.97	0.005313
IDEAYA Biosciences Inc	US45166A1025/ IDYA UW	NASDAQ GS	19.7900	1.02	0.059196
Illumina Inc	US4523271090/ ILMN UW	NASDAQ	436.5425	1.99	0.005236
Registered Shs Inari Medical Inc	US45332Y1091/ NARI UW	NASDAQ GS	114.6000	2.17	0.021653
Incyte Corp	US45337C1027/ INCY UW	NASDAQ	90.8000	1.93	0.024314
Insulet Corp	US45784P1012/ PODD UW	NASDAQ GS	284.3400	2.01	0.008092
Intellia Therapeutics Inc	US45826J1051/ NTLA UQ	NASDAQ	71.6100	2.03	0.032534
Intuitive Surgical Inc	US46120E6023/ ISRG UW	NASDAQ	769.2825	1.99	0.002964
Invitae Corp	US46185L1035/ New York Stock		49.9900	1.84	0.042175

IQVIA Holdings Inc	NVTA UN US46266C1053/ IQV UN	Exchange New York Stock Exchange	186.7400	1.97	0.012094
Moderna Inc	US60770K1079/ MRNA UW	NASDAQ	179.2700	2.12	0.013522
NanoString Technologies Inc	US63009R1095/ NSTG UQ	NASDAQ GM	77.5300	1.01	0.014892
Neurocrine Biosciences Inc	US64125C1099/ NBIX UW	NASDAQ	117.4250	2.01	0.019611
NovoCure Limited	JE00BYSS4X48/ NVCR UW	NASDAQ	178.9800	2.01	0.012897
Pacific Biosciences of California Inc	US69404D1081/ PACB UW	NASDAQ GS	38.6300	2.70	0.080192
Personalis Inc	US71535D1063/ PSNL UQ	NASDAQ GM	42.2551	1.51	0.040966
Pluristem Therapeutics Inc	US72940R3003/ PSTI UQ	NASDAQ GM	7.2400	1.08	0.171729
PRA Health Sciences Inc	US69354M1080/ PRAH UW	NASDAQ GS	122.4100	1.94	0.018185
Precision BioSciences Inc	US74019P1084/ DTIL UW	NASDAQ GS	15.2073	1.06	0.080045
Quest Diagnostics Inc	US74834L1008/ DGX UN	New York Stock Exchange	123.1700	1.88	0.017463
Regeneron Pharmaceuticals Inc	US75886F1075/ REGN UW	NASDAQ GS	502.1205	2.96	0.006750
Sangamo Therapeutics Inc	US8006771062/ SGMO UW	NASDAQ	14.6200	1.01	0.079137
Schrodinger Inc	US80810D1037/ SDGR UW	NASDAQ	101.3240	1.53	0.017333
Seagen Inc	US81181C1045/ SGEN UW	NASDAQ GS	178.3856	2.11	0.013586
Sorrento Therapeutics Inc	US83587F2020/ SRNE UR	NASDAQ CM	14.2100	0.98	0.079090
Syneos Health Inc	US87166B1026/ SYNH UW	NASDAQ GS	76.5000	1.93	0.028871
Teladoc Health Inc	US87918A1051/ TDOC UN	New York Stock Exchange	289.9350	4.12	0.016297
Thermo Fisher Scientific Inc	US8835561023/ TMO UN	New York Stock Exchange	498.5600	1.91	0.004398
Twist Bioscience Corporation	US90184D1000/ TWST UW	NASDAQ	171.1201	1.74	0.011637
Uniqure B.V.	NL0010696654/ QURE UW	NASDAQ GS	38.5001	1.03	0.030744
Veracyte Inc	US92337F1075/ VCYT UQ	NASDAQ GM	76.0700	0.99	0.014982
Zai Lab Ltd	US98887Q1040/ ZLAB UQ	NASDAQ	181.7600	2.04	0.012882

\* Local taxes, transactions fees and foreign commissions are, if applicable, included in the Initial Fixing Value of each component and are thus borne by the holders of the Structured Product. This applies particularly, though not exclusively, when exercising rights associated with the Structured Product and/or a Rebalancing.

## Corporate Actions

Date	Underlying	Action		
		Rebalancing on 08.02.2021	Amount old	Amount new
08.02.2021	10x Genomics Inc	Rebalancing	0.012340	0.012320
08.02.2021	Abiomed Inc	Rebalancing	0.003382	0.003376
08.02.2021	Allakos Inc	Rebalancing	0.012131	0.012111
08.02.2021	AquaBounty Technologies Inc	Rebalancing	0.102169	0.102000
08.02.2021	Arcturus Therapeutics Holdings Inc	Rebalancing	0.013763	0.013740
08.02.2021	Arcus Biosciences Inc	Rebalancing	0.042248	0.042178
08.02.2021	Arvinas Inc	Rebalancing	0.020299	0.020265
08.02.2021	Beam Therapeutics Inc	Rebalancing	0.016629	0.016602
08.02.2021	BeiGene Ltd	Rebalancing	0.006162	0.006152
08.02.2021	Biomarin Pharmaceutical Inc	Rebalancing	0.026682	0.026638
08.02.2021	Bionano Genomics Inc	Rebalancing	0.234429	0.234042
08.02.2021	BioTelemetry Inc	Sell	0.015491	-
08.02.2021	BioXcel Therapeutics Inc	Buy	-	0.018960
08.02.2021	Castle Biosciences Inc	Rebalancing	0.013440	0.013418
08.02.2021	Cerner Corp	Rebalancing	0.027838	0.027792
08.02.2021	Charles River Laboratories International Inc	Rebalancing	0.008315	0.008301
08.02.2021	Codexis Inc	Rebalancing	0.039900	0.039834
08.02.2021	Coherus BioSciences Inc	Rebalancing	0.127836	0.127625
08.02.2021	CRISPR Therapeutics AG	Rebalancing	0.020163	0.020130
08.02.2021	Dexcom Inc	Rebalancing	0.005717	0.005708
08.02.2021	Editas Medicine Inc	Rebalancing	0.035140	0.035082
08.02.2021	Exact Sciences Corp	Rebalancing	0.023750	0.023711
08.02.2021	Globus Medical Inc	Rebalancing	0.035707	0.035648
08.02.2021	Guardant Health Inc	Rebalancing	0.014044	0.014021
08.02.2021	Icon PLC	Rebalancing	0.010978	0.010960
08.02.2021	ICU Medical Inc	Rebalancing	0.005322	0.005313
08.02.2021	IDEAYA Biosciences Inc	Rebalancing	0.059294	0.059196
08.02.2021	Illumina Inc	Rebalancing	0.005245	0.005236
08.02.2021	Incyte Corp	Rebalancing	0.024354	0.024314
08.02.2021	Insulet Corp	Rebalancing	0.008105	0.008092
08.02.2021	Intellia Therapeutics Inc	Rebalancing	0.032588	0.032534
08.02.2021	Intuitive Surgical Inc	Rebalancing	0.002969	0.002964
08.02.2021	Invitae Corp	Rebalancing	0.042245	0.042175
08.02.2021	IQVIA Holdings Inc	Rebalancing	0.012114	0.012094
08.02.2021	Moderna Inc	Rebalancing	0.013544	0.013522
08.02.2021	NanoString Technologies Inc	Rebalancing	0.014917	0.014892
08.02.2021	Neurocrine Biosciences Inc	Rebalancing	0.019643	0.019611
08.02.2021	NovoCure Limited	Rebalancing	0.012918	0.012897
08.02.2021	Pacific Biosciences of California Inc	Rebalancing	0.080325	0.080192
08.02.2021	Personalis Inc	Rebalancing	0.041034	0.040966
08.02.2021	Pluristem Therapeutics Inc	Rebalancing	0.172013	0.171729
08.02.2021	PRA Health Sciences Inc	Rebalancing	0.018215	0.018185
08.02.2021	Precision BioSciences Inc	Rebalancing	0.080177	0.080045
08.02.2021	Quest Diagnostics Inc	Rebalancing	0.017492	0.017463
08.02.2021	Regeneron Pharmaceuticals Inc	Rebalancing	0.006761	0.006750
08.02.2021	Registered Shs Inari Medical Inc	Rebalancing	0.021689	0.021653
08.02.2021	Sangamo Therapeutics Inc	Rebalancing	0.079268	0.079137
08.02.2021	Schrodinger Inc	Rebalancing	0.017362	0.017333
08.02.2021	Seagen Inc	Rebalancing	0.013608	0.013586
08.02.2021	Sorrento Therapeutics Inc	Rebalancing	0.079221	0.079090
08.02.2021	Syneos Health Inc	Rebalancing	0.028919	0.028871
08.02.2021	Teladoc Health Inc	Rebalancing	0.016324	0.016297
08.02.2021	Thermo Fisher Scientific Inc	Rebalancing	0.004405	0.004398
08.02.2021	Twist Bioscience Corporation	Rebalancing	0.011656	0.011637
08.02.2021	Uniqure B.V.	Rebalancing	0.030795	0.030744
08.02.2021	Veracyte Inc	Rebalancing	0.015007	0.014982
08.02.2021	Zai Lab Ltd	Rebalancing	0.012903	0.012882